Emerging therapies for MASLD and their impact on plasma lipids

Madison Nguyen; Amon Asgharpour; Dave L Dixon; Arun J Sanyal; Anurag Mehta

doi:10.1016/j.ajpc.2024.100638

Emerging therapies for MASLD and their impact on plasma lipids

Am J Prev Cardiol. 2024 Feb 5:17:100638. doi: 10.1016/j.ajpc.2024.100638. eCollection 2024 Mar.

Authors

Madison Nguyen¹, Amon Asgharpour^{1

2}, Dave L Dixon^{3

4}, Arun J Sanyal^{1

2}, Anurag Mehta^{1

4}

Affiliations

¹ Department of Internal Medicine, Virginia Commonwealth University School of Medicine, Richmond, VA, United States.
² VCU Stravitz-Sanyal Institute of Liver Disease and Metabolic Health, Richmond, VA, United States.
³ Department of Pharmacotherapy and Outcome Science, Virginia Commonwealth University School of Pharmacy, Richmond, VA, United States.
⁴ VCU Health Pauley Heart Center, Richmond, VA, United States.

Abstract

Metabolic-dysfunction associated steatotic liver disease (MASLD) affects 1 out of every 3 individuals in the adult population and the disease prevalence is predicted to increase worldwide. Patients with MASLD are also burdened by cardiovascular disease, which is the leading cause of mortality in this population. Complex metabolic derangements such as insulin resistance and atherogenic dyslipidemia affect patients with MASLD. In patients with MASLD, treatment such as pharmacotherapy may be best directed towards improving the adverse concomitant metabolic disorders associated with MASLD, particularly the ones that may contribute to MASLD. Herein, we discuss conventional therapies that target cardiometabolic risk factors which have the potential to improve hepatic injury, and summarize emerging therapies that target hepatic receptors, fibrosis, and fatty acid oxidation in patients with MASLD. Given the relationship between hepatic injury which leads to MASLD, insulin resistance, and ultimately atherogenic dyslipidemia our review uniquely delves into the effects of conventional and emerging therapies for MASLD on plasma lipid parameters.

Keywords: Atherosclerosis; Cardiometabolic disease; Dyslipidemia; Metabolic-dysfunction associated steatohepatitis; Metabolic-dysfunction associated steatotic liver disease.